Jomed JoStent
This article was originally published in The Gray Sheet
Executive Summary
U.S. shipments of the coronary stent for treatment of free perforations in native coronary vessels or saphenous vein bypass grafts are expected to commence in the second quarter following FDA humanitarian device exemption approval Jan. 10. The device will be marketed by the Swiss firm's 50-rep U.S. sales force. The market for the $2,200 stent is estimated at 3,000-4,000 units annually